Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fennec Pharmaceuticals Inc. on May 17, 2017. The report addresses a change in the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Resignation of Prior Auditor: Deloitte LLP advised the Company it would resign as of May 15, 2017.
- Appointment of New Auditor: The Audit Committee approved the appointment of Haskell & White LLP as the independent registered public accounting firm on May 15, 2017.
- Audit History: Deloitte's reports for fiscal years 2016 and 2015 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements with Deloitte regarding accounting principles, practices, or audit scope during those years or the interim period through May 15, 2017.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No reportable events or disagreements were identified during the transition period. The Company confirmed that it has not consulted with the new auditor, Haskell & White LLP, regarding accounting principles or audit opinions prior to their appointment.
Investor Verification Checklist
- Verify the reasons for Deloitte LLP's resignation by reviewing the letter filed as Exhibit 16.1.
- Confirm the qualifications and independence of the newly appointed auditor, Haskell & White LLP.
- Review subsequent filings to ensure the transition of audit responsibilities did not impact the timeliness of future financial reporting.